Purpose We report the experience with 2,000 consecutive patients with advanced cancer
who underwent testing on a genomic testing protocol, including the frequency of actionable …

Background Antiresorptive drugs (ARD) are associated with a known serious adverse event,
known as medication-related osteonecrosis of the jaws (MRONJ). Transition from one ARD …

Purpose: Alpelisib, a selective oral inhibitor of the class I PI3K catalytic subunit p110α, has
shown synergistic antitumor activity with endocrine therapy against ER+/PIK3CA-mutated …

Importance Given recent advances in screening mammography and adjuvant therapy
(treatment), quantifying their separate and combined effects on US breast cancer mortality …

Background Building on earlier work, the toxicity probability interval (TPI) method, we
present a modified TPI (mTPI) design that is calibration-free for phase I trials. Purpose Our …

Objective: Although there has been a socioeconomic gradient in smoking prevalence,
cessation, and disease burden for decades, these disparities have become even more …

Objectives. We examined the influence of tobacco outlet density and residential proximity to
tobacco outlets on continuous smoking abstinence 6 months after a quit attempt. Methods …

Abstract Background The PI3K/AKT pathway is activated through PIK3CA or AKT1 mutations
and PTEN loss in breast cancer. We conducted a phase II trial with an allosteric AKT …

Objectives. We examined associations between health literacy and predictors of smoking
cessation among 402 low-socioeconomic status (SES), racially/ethnically diverse smokers …

Purpose Buparlisib, an oral reversible inhibitor of all class I phosphoinositide-3-kinases, has
shown antitumoral activity against estrogen receptor (ER)-positive breast cancer cell lines …